Beta Bionics (NASDAQ:BBNX) Now Covered by Piper Sandler

Piper Sandler started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report issued on Monday, MarketBeat Ratings reports. The firm issued an overweight rating and a $26.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Leerink Partners began coverage on Beta Bionics in a report on Monday. They issued an “outperform” rating and a $28.00 target price for the company. Baird R W raised Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Finally, LADENBURG THALM/SH SH began coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Stock Up 4.3 %

BBNX stock opened at $19.99 on Monday. Beta Bionics has a 1 year low of $18.67 and a 1 year high of $24.50.

Insider Buying and Selling at Beta Bionics

In other news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mike Mensinger purchased 33,350 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the acquisition, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.